Your browser doesn't support javascript.
loading
Determination of genetic predisposition to patent ductus arteriosus in preterm infants.
Dagle, John M; Lepp, Nathan T; Cooper, Margaret E; Schaa, Kendra L; Kelsey, Keegan J P; Orr, Kristin L; Caprau, Diana; Zimmerman, Cara R; Steffen, Katherine M; Johnson, Karen J; Marazita, Mary L; Murray, Jeffrey C.
Afiliação
  • Dagle JM; Department of Pediatrics, University of Iowa, Iowa City, IA 52242, USA. john-dagle@uiowa.edu
Pediatrics ; 123(4): 1116-23, 2009 Apr.
Article em En | MEDLINE | ID: mdl-19336370
ABSTRACT

OBJECTIVE:

Patent ductus arteriosus is a common morbidity associated with preterm birth. The incidence of patent ductus arteriosus increases with decreasing gestational age to approximately 70% in infants born at 25 weeks' gestation. Our major goal was to determine if genetic risk factors play a role in patent ductus arteriosus seen in preterm infants.

METHODOLOGY:

We investigated whether single-nucleotide polymorphisms in genes that regulate smooth muscle contraction, xenobiotic detoxification, inflammation, and other processes are markers for persistent patency of ductus arteriosus. Initially, 377 single-nucleotide polymorphisms from 130 genes of interest were evaluated in DNA samples collected from 204 infants with a gestational age of <32 weeks. A family-based association test was performed on genotyping data to evaluate overtransmission of alleles.

RESULTS:

P values of <.01 were detected for genetic variations found in 7 genes. This prompted additional analysis with an additional set of 162 infants, focusing on the 7 markers with initial P values of <.01, and 1 genetic variant in the angiotensin II type I receptor previously shown to be related to patent ductus arteriosus. Of the initial positive signals, single-nucleotide polymorphisms in the transcription factor AP-2 beta and tumor necrosis factor receptor-associated factor 1 genes remained significant. Additional haplotype analysis revealed genetic variations in prostacyclin synthase to be associated with patent ductus arteriosus. An angiotensin II type I receptor polymorphism previously reported to be associated with patent ductus arteriosus after prophylactic indomethacin administration was not associated with the presence of a patent ductus arteriosus in our population.

CONCLUSIONS:

Overall, our data support a role for genetic variations in transcription factor AP-2 beta, tumor necrosis factor receptor-associated factor 1, and prostacyclin synthase in the persistent patency of the ductus arteriosus seen in preterm infants.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Predisposição Genética para Doença / Polimorfismo de Nucleotídeo Único / Permeabilidade do Canal Arterial / Doenças do Prematuro Idioma: En Ano de publicação: 2009 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Predisposição Genética para Doença / Polimorfismo de Nucleotídeo Único / Permeabilidade do Canal Arterial / Doenças do Prematuro Idioma: En Ano de publicação: 2009 Tipo de documento: Article